MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Rhea-AI Summary

MAIA (NYSE American: MAIA) announced that independent directors participated in a private placement that closed on December 22, 2025, with three directors buying a total of 179,737 shares and 179,737 warrants at an average price of $1.224.

Gross proceeds from the offering were approximately $1.51 million. Directors and officers now hold 5,019,857 shares, equal to 13.43% of MAIA. The company said the financing reflects confidence in ateganosine, its first-in-class anticancer therapy; MAIA launched a pivotal Phase 3 international trial in December 2025 and the FDA granted Fast Track designation for ateganosine in NSCLC.

Positive

• Pivotal Phase 3 trial launched in Dec 2025
• FDA granted Fast Track designation for ateganosine
• Directors bought 179,737 shares and 179,737 warrants
• Gross proceeds of approximately $1.51M
• Directors & officers hold 5,019,857 shares (13.43%)

Negative

• None.

Key Figures

Director shares purchased 179,737 shares Director participation in Dec 22, 2025 private placement

Director warrants 179,737 warrants Matching warrants purchased in same financing

Average purchase price $1.224 Director participation in recent private placement

Gross proceeds $1.51 million Total gross proceeds from recent private placement

Insider ownership 5,019,857 shares Directors and officers total holdings

Insider ownership stake 13.43% Directors and officers percentage of MAIA

Market Reality Check

$1.57 Last Close

Volume Volume 653,948 is below the 20-day average of 975,624, suggesting no unusual trading ahead of this update. low

Technical Shares at $1.36 are trading below the 200-day moving average of $1.58 and about 50% under the 52-week high of $2.74.

Peers on Argus

MAIA’s pre-news move of +2.26% contrasted with declines across key biotech peers (e.g., CUE -6.38%, QNTM -12%), indicating stock-specific dynamics rather than a sector-wide rally.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 16	Private placement	Positive	-8.9%	Announced $1.51M private placement at $1.224 with 3-year warrants.
Dec 11	Clinical trial update	Positive	+18.8%	Initiation of pivotal Phase 3 ateganosine trial with Fast Track designation.
Dec 11	Clinical milestone	Positive	+18.8%	First patient dosed in THIO-104 Phase 3 trial for advanced NSCLC.
Dec 11	Insider buying/news	Positive	+18.8%	Reported additional 2025 insider purchases and ateganosine clinical progress.
Dec 10	Market opportunity	Positive	+2.2%	Outlined ateganosine’s role in large NSCLC and immunotherapy markets.

Pattern Detected

Recent news skewed positive (clinical progress, insider buying), with four of five events showing price gains; only the December private placement drew a negative reaction.

Recent Company History

Over the past weeks, MAIA has highlighted ateganosine’s advancement, including initiation of a pivotal Phase 3 THIO-104 trial and FDA Fast Track designation for NSCLC. News on Dec 10–11 tied the program to large oncology markets and reported first patient dosing, driving several +18.84% moves. A $1.51M private placement announced on Dec 16 saw a -8.89% reaction. Today’s director participation update extends the 2025 insider buying and financing narrative.

Market Pulse Summary

The stock moved +8.8% in the session following this news. A strong positive reaction aligns with recent patterns where MAIA’s stock often moved higher on clinical milestones and insider buying, as seen with several +18.84% days in mid-December. However, the -8.89% response to the prior private placement shows financings can weigh on sentiment. Continued director participation and rising insider ownership support confidence, but additional capital raises or shifts in trial progress could temper sustainability.

Key Terms

private placement financial

"purchased common stock and warrants in the recent private placement offering"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

warrants financial

"purchased common stock and warrants in the recent private placement"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Phase 3 medical

"advance our pivotal Phase 3 international trial launched this month"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

Fast Track designation regulatory

"The U.S. Food and Drug Administration (FDA) has granted Fast Track designation"

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

non-small cell lung cancer medical

"treatment for advanced non-small cell lung cancer (NSCLC)"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

NSCLC medical

"treatment for advanced non-small cell lung cancer (NSCLC)"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

AI-generated analysis. Not financial advice.

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine

CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that independent directors including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D. purchased common stock and warrants in the recent private placement offering which closed on December 22, 2025.

Three directors purchased a total of 179,737 shares and 179,737 warrants with an average purchase price of $1.224. Dr. Smith has invested in all of MAIA’s funding rounds since the Company’s inception in 2018, and Ms. Adelina Louie is a top investor in MAIA. Gross proceeds from the offering totaled approximately $1.51 million.

To date, directors and officers hold 5,019,857 shares or 13.43% of MAIA.

“Ongoing support from our directors reflects their strong conviction in the commercial potential of ateganosine, our first-in-class anticancer treatment for advanced non-small cell lung cancer (NSCLC),” said Vlad Vitoc, M.D., founder and CEO of MAIA. “Consistent insider participation in our 2025 financings strengthens our ability to execute as we advance our pivotal Phase 3 international trial launched this month with first patient dosing.”

Dr. Smith commented, “Our continued support reflects our strong confidence in the scientific differentiation and commercial promise of ateganosine. The initiation of the pivotal Phase 3 trial marks an important value-creation milestone for MAIA.”

Ms. Adelina Louie stated, “I believe MAIA has reached a pivotal stage in advancing life-changing therapies to broad populations of patients with cancer, and I am proud continue to support the Company in my capacity as both an investor and a member of the Board.”

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC. Statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

FAQ

What did MAIA announce about insider participation on December 22, 2025?

Three directors purchased a total of 179,737 shares and 179,737 warrants at an average price of $1.224 in the private placement.

How much did MAIA raise in the December 2025 private placement (MAIA)?

Gross proceeds from the offering totaled approximately $1.51 million.

What ownership stake do MAIA directors and officers hold after the financing?

Directors and officers hold 5,019,857 shares, representing 13.43% of MAIA.

What clinical milestone did MAIA announce in December 2025 for ateganosine (MAIA)?

MAIA launched a pivotal Phase 3 international trial for ateganosine in December 2025 with first patient dosing.

Does ateganosine have any regulatory designations from the FDA for NSCLC?

Yes; the FDA granted Fast Track designation for ateganosine for treatment of non-small cell lung cancer.

What rationale did MAIA give for director participation in the private placement (MAIA)?

Company statements said the purchases reflect directors' confidence in the scientific differentiation and commercial potential of ateganosine.